MMUNOLOGY & MICROBIOLOGY
Within the department of Immunology & Microbiology at The Scripps Research Institute, the following postdoctoral position is available:
Principal Investigator: Philippe Gallay
Hepatitis B virus (HBV) infection is a major health burden worldwide with 240 million chronically infected individuals. Nucleos(t)ide analogs and interferons are the current standards of care due to their suppression of HBV replication, but the treatments fail to eradicate HBV from individuals. Therefore, new strategies are absolutely required to cure HBV. Our laboratory recently identified a novel approach showing solid premises to provide such a cure.
Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide, accounting for over half a million deaths per year. Chronic infections with hepatitis B (HBV) and C (HCV) viruses have been recognized as main human liver carcinogens. Multiple non-viral factors have also been implicated in the development of HCC. The development of non-alcoholic steatohepatitis (NASH) and liver fibrosis represent high risk factors for HCC. Remarkably, we recently found that cyclophilin inhibitors suppress the development of viral-induced and non-viral-induced liver fibrosis and HCC in mouse models. However, their mechanisms of action are totally unknown.
Positions: A postdoctoral position is immediately available to study the cure of HBV using in vivo and in vitro HBV infectious models and to study the protective effects of cyclophilin inhibitors in liver damage mouse models.
Lab publications: https://www.ncbi.nlm.nih.gov/sites/myncbi/philippe.gallay.1/bibliography/40512871/public/?page=1
Please send CV and three professional references to firstname.lastname@example.org.